{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:57:20Z","timestamp":1773316640192,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":3037,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.fertnstert.2013.10.015","type":"journal-article","created":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T16:00:25Z","timestamp":1384012825000},"page":"496-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study"],"prefix":"10.1016","volume":"101","clinical-trial-number":[{"clinical-trial-number":"nct00881140","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gil M.","family":"Yerushalmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinon","family":"Gilboa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariella","family":"Jakobson-Setton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yona","family":"Tadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Goldchmit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2013.10.015_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.AOG.0000136079.62513.39","article-title":"Uterine myomas: an overview of development, clinical features, and management","volume":"104","author":"Wallach","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.fertnstert.2007.06.044","article-title":"Uterine myomas: management","volume":"88","author":"Parker","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0015-0282(16)59763-5","article-title":"A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri","volume":"49","author":"Friedman","year":"1988","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib4","first-page":"CD008994","article-title":"Progestogens or progestogen-releasing intrauterine systems for uterine fibroids","volume":"2","author":"Sangkomkamhang","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib5","first-page":"CD007687","article-title":"Mifepristone for uterine fibroids","volume":"8","author":"Tristan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/oxfordjournals.humrep.a136608","article-title":"Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans","volume":"2","author":"Heikinheimo","year":"1987","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1997.tb48550.x","article-title":"The first uterine pass effect","volume":"828","author":"De Ziegler","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/humrep\/12.5.1073","article-title":"Targeted drug delivery in gynaecology: the first uterine pass effect","volume":"12","author":"Bulletti","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib11","first-page":"290","article-title":"The UFS-QoL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata","volume":"99","author":"Spies","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1477-7525-6-99","article-title":"The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QoL)","volume":"6","author":"Harding","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/IJWH.S28103","article-title":"Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery","volume":"4","author":"Carbonell Esteve","year":"2012","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejogrb.2009.06.004","article-title":"Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata","volume":"146","author":"Eisinger","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0015-0282(16)57678-X","article-title":"Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect","volume":"64","author":"Murphy","year":"1995","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","article-title":"Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial","volume":"161","author":"Esteve","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0300-1652.86123","article-title":"A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri","volume":"52","author":"Mukherjee","year":"2011","journal-title":"Niger Med J"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/01.AOG.0000127622.63269.8b","article-title":"Systematic review of mifepristone for the treatment of uterine leiomyomata","volume":"103","author":"Steinauer","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/uog.4099","article-title":"Clinical improvement and shrinkage of uterine fibroids after thermal ablation by magnetic resonance-guided focused ultrasound surgery","volume":"30","author":"Rabinovici","year":"2007","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib21","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1093\/humrep\/des333","article-title":"MR-guided focus ultrasound (MRgFUS) for symptomatic uterine fibroids: predictors of treatment success","volume":"27","author":"Machtinger","year":"2012","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","article-title":"Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial","volume":"112","author":"Carbonell Esteve","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1210\/jc.2008-2093","article-title":"Progestins activate the AKT pathway in leiomyoma cells and promote survival","volume":"94","author":"Hoekstra","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmig.2005.01.022","article-title":"Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas","volume":"12","author":"Eisinger","year":"2005","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.fertnstert.2013.10.015_bib25","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","article-title":"Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial","volume":"24","author":"Engman","year":"2009","journal-title":"Hum Reprod"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028213031610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028213031610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:59:41Z","timestamp":1773251981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028213031610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0015028213031610"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2013.10.015","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2013.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}